查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
肝纤维化市场－全球与区域分析、区域分析与预测（2025-2035）
市场调查报告书
商品编码
1818891

肝纤维化市场－全球与区域分析、区域分析与预测（2025-2035）

Liver Fibrosis Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035
出版日期: | 出版商: BIS Research | 英文 100 Pages | 商品交期: 1-5个工作天内

价格

全球肝纤维化市场 - 分析与预测（2025-2035）

肝纤维化是一种进行性性肝病，其特征是由于多种潜在疾病（包括肝炎、饮酒、肥胖和自体免疫疾病）引起的慢性肝损伤导致肝臟中疤痕组织的积聚。

当肝臟试图自我修復损伤时，胶原蛋白和其他细胞外基质成分的过度生成会导致纤维化。如果不及时治疗，肝纤维化可能会发展为肝硬化、慢性肝功能衰竭，甚至肝癌。肝纤维化的程度通常分为几个阶段，早期阶段可逆，但晚期阶段会导致永久性损伤。

目前，肝纤维化仍然是一个严重的健康问题，但诊断技术和治疗方法的进步使得更有效的治疗成为可能。抗纤维化疗法，例如用于治疗肝炎相关纤维化的抗病毒药物和标靶纤维化途径的药物，已成为重要的治疗选择。肝臟移植是末期肝纤维化和肝硬化的唯一根治性治疗方法，但受捐赠者来源的限制。

各种肝病的盛行率正在稳步上升，包括自体免疫肝炎、非酒精性脂肪性肝病 (NAFLD)、酒精性肝病、慢性乙型和丙型肝炎以及肝纤维化。这些疾病的进展往往导致肝纤维化，而肝纤维化在世界各地正变得越来越普遍。肝纤维化盛行率的上升预计将推动其治疗市场的发展。主要风险因素，如慢性B型和C型肝炎、合併感染爱滋病毒/爱滋病以及肝臟移植后使用免疫抑制剂，导致对肝纤维化治疗的需求不断增长。根据美国国家生物技术资讯中心的一项研究，预计到 2023 年肝病将成为全球主要的健康问题，约占全球死亡率的 4%。因此，全球肝纤维化患者数量的快速增加将进一步推动市场成长。

此外，我们对肝纤维化分子机制的日益深入理解也推动了标靶治疗的发展。对特定纤维化路径（例如TGF-β讯号传导和免疫细胞在纤维化进展中的作用）的研究，已促成了有前景的治疗药物的发现。肝弹性成像和血液生物标记等非侵入性诊断工具促进了肝纤维化的早期发现，从而能够更及时地进行干预并更好地管理疾病。

儘管取得了这些进展，肝纤维化市场仍面临许多挑战。其中一个主要障碍是缺乏核准的有效抗纤维化疗法。虽然有多种候选药物正在临床试验中，但核准用于治疗肝纤维化（尤其是晚期）的药物却寥寥无几。这导致重度肝纤维化和肝硬化患者的治疗选择出现空白。此外，肝纤维化疾病及其进展的复杂性，以及在非侵入性手术的情况下难以准确分期肝纤维化，使得诊断和治疗都变得复杂。

另一个挑战是治疗费用高昂，尤其是肝臟移植和针对纤维化的新型生物製药等先进疗法。这些治疗通常价格昂贵，给医疗保健系统和患者带来经济负担，尤其是在医疗资源有限的开发中地区。

全球肝纤维化市场竞争激烈，Akero Therapeutics、Sagimet Biosciences、Inventiva Pharma、Novo Nordisk、Viking Therapeutics、Boston Pharmaceuticals、Aligos Therapeutics、Boehringer Ingelheim 和 89bio 等主要企业推动创新和市场成长。这些公司在开发可显着改善患者预后的新治疗方法处于领先地位。透过对研发 (R&D) 的策略性投资、扩大产品系列以及增加全球获得最先进治疗的机会，这些行业领导者正在塑造肝纤维化治疗的未来并为市场动态成长做出贡献。此外，扩展到新兴市场并透过区域分销网络加强其影响力是挖掘服务不足的患者群体的关键策略。这些策略使公司能够加强其市场地位并加速竞争激烈的肝纤维化治疗市场中的成长。

肝纤维化市场细分

细分1：按地区

  • 北美洲
  • 欧洲
  • 亚太地区

全球肝纤维化市场正经历重大变革时期，新兴趋势正在重塑治疗模式，推动市场成长。人工智慧 (AI) 与肝纤维化治疗的结合，蕴藏着巨大的潜力，有望彻底改变诊断和治疗方式。透过分析大量患者数据，包括影像、生物标记和基因讯息，AI 可以显着提高早期准确诊断肝纤维化的能力。机器学习演算法已被开发用于解读弹性成像和电脑断层扫描等非侵入性检查，从而能够更快、更可靠地评估肝损伤，从而提高诊断速度并实现早期疗育。

肝纤维化市场向新兴地区的扩张代表着巨大的成长机会，这得益于多种因素。随着亚太、拉丁美洲和非洲部分地区医疗基础设施的改善，肝纤维化治疗的需求预计将上升。在这些地区，肝病的盛行率正在上升，尤其是肥胖、饮酒和肝炎等风险因素日益普遍。此外，这些地区的人口老化也导致慢性肝病和肝纤维化的发生率上升。

目录

执行摘要

第一章全球肝纤维化市场：产业分析

  • 市场概况与生态系统
  • 流行病学分析
  • 主要市场趋势
    • 影响分析
  • 监管状况
  • 管道分析
  • 市场动态
    • 概述
    • 市场驱动因素
    • 市场限制
    • 市场机会

2. 全球肝纤维化市场（按地区）价值，2023-2035

  • 北美洲
    • 市场动态
    • 市场规模及预测
    • 北美肝纤维化市场（按国家/地区，百万美元），2023-2035 年
  • 欧洲
    • 市场动态
    • 市场规模及预测
    • 欧洲肝纤维化市场（按国家划分，百万美元），2023-2035 年
  • 亚太地区
    • 市场动态
    • 市场规模及预测
    • 亚太肝纤维化市场（按国家/地区，百万美元），2023-2035 年

第三章：竞争格局与公司概况

  • 竞争格局
  • 公司简介
    • Akero Therapeutics
    • Sagimet Biosciences
    • Boehringer Ingelheim
    • 89bio
    • Inventiva Pharma
    • Galmed Pharmaceuticals
    • Novo Nordisk A/S
    • Viking Therapeutics
    • Hepion Pharmaceuticals
    • Pfizer, Inc.
    • HighTide Biopharma
    • Boston Pharmaceuticals
    • Rivus Pharmaceuticals
    • Lipocine
    • Aligos Therapeutics
    • MediciNova
    • Eli Lilly and Company
    • 其他的

第四章调查方法

Product Code: BHL3270SA

Global Liver Fibrosis Market, Analysis and Forecast: 2025-2035

Liver fibrosis is a progressive liver disease characterized by the accumulation of scar tissue in the liver, resulting from chronic liver damage due to various underlying conditions such as hepatitis, alcohol use, obesity, or autoimmune diseases. As the liver attempts to heal itself from injury, excessive collagen and other extracellular matrix components are produced, leading to fibrosis. If left untreated, liver fibrosis can progress to cirrhosis, chronic liver failure, or even liver cancer. The severity of liver fibrosis is often classified into stages, with early stages being reversible but more advanced stages leading to permanent damage.

While liver fibrosis is currently a significant health concern, advancements in diagnostic technologies and treatments are helping to manage the disease more effectively. Antifibrotic therapies, such as antivirals for hepatitis-related fibrosis and medications that target fibrosis pathways, are emerging as key treatment options. Liver transplantation remains the only definitive cure for end-stage liver fibrosis or cirrhosis, though it is limited by donor availability.

The prevalence of various liver diseases, including autoimmune hepatitis, non-alcoholic fatty liver disease (NAFLD), alcoholic liver disease, chronic hepatitis B and C, and liver fibrosis, is steadily increasing. As these conditions progress, they often lead to liver fibrosis, which is becoming more common globally. The growing incidence of liver fibrosis is expected to drive the market for its treatment. Key risk factors such as chronic hepatitis B or C, co-infection with HIV/AIDS, and the use of immunosuppressive drugs following liver transplantation are contributing to the rising demand for liver fibrosis treatments. According to a study by the National Center for Biotechnology Information, liver disease is projected to become a major global health issue in 2023, contributing to an estimated 4% of global mortality. Thus, the worldwide surge in liver fibrosis cases is further propelling market growth.

Additionally, the growing understanding of the molecular mechanisms involved in liver fibrosis is fuelling the development of targeted therapies. Research into specific fibrosis pathways, such as TGF-B signaling and the role of immune cells in fibrosis progression, has led to the discovery of promising therapeutic agents. Non-invasive diagnostic tools, such as liver elastography and blood biomarkers, are also making it easier to detect liver fibrosis early, enabling more timely intervention and better management of the disease.

Despite these advances, the liver fibrosis market faces several challenges. One significant hurdle is the lack of approved, effective antifibrotic therapies. While several drug candidates are in clinical trials, there are few approved therapies available to treat liver fibrosis, especially for advanced stages. This has led to a gap in treatment options for patients with severe fibrosis or cirrhosis. Moreover, the complexity of the disease and its progression, along with the difficulty of accurately staging liver fibrosis without invasive procedures, complicates both diagnosis and treatment.

Another challenge is the high cost of treatment, particularly for advanced therapies such as liver transplantation and novel biologics targeting fibrosis. These treatments often come with high costs, placing financial strain on healthcare systems and patients, especially in developing regions where access to care may be limited.

The global liver fibrosis market is highly competitive, with several leading companies driving innovation and market growth, such as Akero Therapeutics, Sagimet Biosciences, Inventiva Pharma, Novo Nordisk, Viking Therapeutics, Boston Pharmaceuticals, Aligos Therapeutics, Boehringer Ingelheim, and 89bio. These companies are at the forefront of developing novel therapies that are significantly improving patient outcomes. Through strategic investments in research and development (R&D), expanding product portfolios, and increasing global access to cutting-edge treatments, these industry leaders are shaping the future of liver fibrosis care and contributing to the dynamic growth of the market. Additionally, expanding into emerging markets and increasing their presence through regional distribution networks are key strategies to tap into underserved patient populations. These strategies are enabling companies to strengthen their market position and accelerate growth in the competitive liver fibrosis treatment landscape.

Liver Fibrosis Market Segmentation:

Segmentation 1: by Region

  • North America
  • Europe
  • Asia-Pacific

The global liver fibrosis market is undergoing significant transformation, fueled by emerging trends that are reshaping treatment paradigms and driving liver fibrosis market growth. The integration of artificial intelligence (AI) into liver fibrosis treatment holds immense potential to revolutionize both diagnosis and treatment. AI can significantly enhance the ability to diagnose liver fibrosis early and accurately by analyzing vast amounts of patient data, including imaging, biomarkers, and genetic information. Machine learning algorithms are already being developed to interpret non-invasive tests like elastography and CT scans, offering faster and more reliable assessments of liver damage, which can improve the speed of diagnosis and allow for earlier intervention.

The expansion of the liver fibrosis market into emerging regions presents a significant growth opportunity due to several factors. As healthcare infrastructure improves in regions such as Asia-Pacific, Latin America, and parts of Africa, the demand for liver fibrosis treatments is expected to rise. These regions are witnessing an increasing prevalence of liver diseases, particularly as risk factors such as obesity, alcohol consumption, and hepatitis become more widespread. Furthermore, the aging population in these regions is leading to a higher incidence of chronic liver diseases and fibrosis.

Table of Contents

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

1. Global Liver Fibrosis Market: Industry Analysis

  • 1.1 Market Overview and Ecosystem
  • 1.2 Epidemiological Analysis
  • 1.3 Key Market Trends
    • 1.3.1 Impact Analysis
  • 1.4 Regulatory Landscape
  • 1.5 Pipeline Analysis
  • 1.6 Market Dynamics
    • 1.6.1 Overview
    • 1.6.2 Market Drivers
    • 1.6.3 Market Restraints
    • 1.6.4 Market Opportunities

2. Global Liver Fibrosis Market (Region), Value ($Million), 2023-2035

  • 2.1 North America
    • 2.1.1 Market Dynamics
    • 2.1.2 Market Sizing and Forecast
    • 2.1.3 North America Liver Fibrosis Market, by Country ($Million), 2023-2035
      • 2.1.3.1 U.S.
  • 2.2 Europe
    • 2.2.1 Market Dynamics
    • 2.2.2 Market Sizing and Forecast
    • 2.2.3 Europe Liver Fibrosis Market, by Country ($Million), 2023-2035
      • 2.2.3.1 U.K.
      • 2.2.3.2 France
      • 2.2.3.3 Germany
      • 2.2.3.4 Italy
      • 2.2.3.5 Spain
  • 2.3 Asia-Pacific
    • 2.3.1 Market Dynamics
    • 2.3.2 Market Sizing and Forecast
    • 2.3.3 Asia-Pacific Liver Fibrosis Market, by Country ($Million), 2023-2035
      • 2.3.3.1 Japan

3. Competitive Landscape and Company Profiles

  • 3.1 Competitive Landscape
    • 3.1.1 Mergers and Acquisitions
    • 3.1.2 Partnership, Alliances and Business Expansion
    • 3.1.3 New Offerings
    • 3.1.4 Regulatory Activities
    • 3.1.5 Funding Activities
  • 3.2 Company Profiles
    • 3.2.1 Akero Therapeutics.
      • 3.2.1.1 Overview
      • 3.2.1.2 Top Products / Product Portfolio
      • 3.2.1.3 Top Competitors
      • 3.2.1.4 Target Customers/End-Users
      • 3.2.1.5 Key Personnel
      • 3.2.1.6 Analyst View
    • 3.2.2 Sagimet Biosciences.
      • 3.2.2.1 Overview
      • 3.2.2.2 Top Products / Product Portfolio
      • 3.2.2.3 Top Competitors
      • 3.2.2.4 Target Customers/End-Users
      • 3.2.2.5 Key Personnel
      • 3.2.2.6 Analyst View
    • 3.2.3 Boehringer Ingelheim.
      • 3.2.3.1 Overview
      • 3.2.3.2 Top Products / Product Portfolio
      • 3.2.3.3 Top Competitors
      • 3.2.3.4 Target Customers/End-Users
      • 3.2.3.5 Key Personnel
      • 3.2.3.6 Analyst View
    • 3.2.4 89bio.
      • 3.2.4.1 Overview
      • 3.2.4.2 Top Products / Product Portfolio
      • 3.2.4.3 Top Competitors
      • 3.2.4.4 Target Customers/End-Users
      • 3.2.4.5 Key Personnel
      • 3.2.4.6 Analyst View
    • 3.2.5 Inventiva Pharma.
      • 3.2.5.1 Overview
      • 3.2.5.2 Top Products / Product Portfolio
      • 3.2.5.3 Top Competitors
      • 3.2.5.4 Target Customers/End-Users
      • 3.2.5.5 Key Personnel
      • 3.2.5.6 Analyst View
    • 3.2.6 Galmed Pharmaceuticals.
      • 3.2.6.1 Overview
      • 3.2.6.2 Top Products / Product Portfolio
      • 3.2.6.3 Top Competitors
      • 3.2.6.4 Target Customers/End-Users
      • 3.2.6.5 Key Personnel
      • 3.2.6.6 Analyst View
    • 3.2.7 Novo Nordisk A/S.
      • 3.2.7.1 Overview
      • 3.2.7.2 Top Products / Product Portfolio
      • 3.2.7.3 Top Competitors
      • 3.2.7.4 Target Customers/End-Users
      • 3.2.7.5 Key Personnel
      • 3.2.7.6 Analyst View
    • 3.2.8 Viking Therapeutics.
      • 3.2.8.1 Overview
      • 3.2.8.2 Top Products / Product Portfolio
      • 3.2.8.3 Top Competitors
      • 3.2.8.4 Target Customers/End-Users
      • 3.2.8.5 Key Personnel
      • 3.2.8.6 Analyst View
    • 3.2.9 Hepion Pharmaceuticals.
      • 3.2.9.1 Overview
      • 3.2.9.2 Top Products / Product Portfolio
      • 3.2.9.3 Top Competitors
      • 3.2.9.4 Target Customers/End-Users
      • 3.2.9.5 Key Personnel
      • 3.2.9.6 Analyst View
    • 3.2.10 Pfizer, Inc.
      • 3.2.10.1 Overview
      • 3.2.10.2 Top Products / Product Portfolio
      • 3.2.10.3 Top Competitors
      • 3.2.10.4 Target Customers/End-Users
      • 3.2.10.5 Key Personnel
      • 3.2.10.6 Analyst View
    • 3.2.11 HighTide Biopharma.
      • 3.2.11.1 Overview
      • 3.2.11.2 Top Products / Product Portfolio
      • 3.2.11.3 Top Competitors
      • 3.2.11.4 Target Customers/End-Users
      • 3.2.11.5 Key Personnel
      • 3.2.11.6 Analyst View
    • 3.2.12 Boston Pharmaceuticals.
      • 3.2.12.1 Overview
      • 3.2.12.2 Top Products / Product Portfolio
      • 3.2.12.3 Top Competitors
      • 3.2.12.4 Target Customers/End-Users
      • 3.2.12.5 Key Personnel
      • 3.2.12.6 Analyst View
    • 3.2.13 Rivus Pharmaceuticals.
      • 3.2.13.1 Overview
      • 3.2.13.2 Top Products / Product Portfolio
      • 3.2.13.3 Top Competitors
      • 3.2.13.4 Target Customers/End-Users
      • 3.2.13.5 Key Personnel
      • 3.2.13.6 Analyst View
    • 3.2.14 Lipocine.
      • 3.2.14.1 Overview
      • 3.2.14.2 Top Products / Product Portfolio
      • 3.2.14.3 Top Competitors
      • 3.2.14.4 Target Customers/End-Users
      • 3.2.14.5 Key Personnel
      • 3.2.14.6 Analyst View
    • 3.2.15 Aligos Therapeutics.
      • 3.2.15.1 Overview
      • 3.2.15.2 Top Products / Product Portfolio
      • 3.2.15.3 Top Competitors
      • 3.2.15.4 Target Customers/End-Users
      • 3.2.15.5 Key Personnel
      • 3.2.15.6 Analyst View
    • 3.2.16 MediciNova.
      • 3.2.16.1 Overview
      • 3.2.16.2 Top Products / Product Portfolio
      • 3.2.16.3 Top Competitors
      • 3.2.16.4 Target Customers/End-Users
      • 3.2.16.5 Key Personnel
      • 3.2.16.6 Analyst View
    • 3.2.17 Eli Lilly and Company.
      • 3.2.17.1 Overview
      • 3.2.17.2 Top Products / Product Portfolio
      • 3.2.17.3 Top Competitors
      • 3.2.17.4 Target Customers/End-Users
      • 3.2.17.5 Key Personnel
      • 3.2.17.6 Analyst View
    • 3.2.18 Others

4. Research Methodology

List of Figures

  • Figure: Global Liver Fibrosis Market Coverage
  • Figure: Global Liver Fibrosis Market Key Trends, Impact Analysis, 2023-2035

List of Tables

  • Table: Global Liver Fibrosis Market Dynamics, Impact Analysis
  • Table: Global Liver Fibrosis Market (by Region), $Million, 2023-2035